Vaccination against the hepatitis A virus (HAV) in children two years of age and younger remains effective for at least ten years, according to new research available in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD). The study found that any transfer of the mother's HAV antibodies does not lower the child's immune response to the vaccine.
The World Health Organization (WHO) estimates that 1.4 million cases of HAV occur worldwide each year. HAV affects the liver and typically occurs in areas with poor sanitation where ingestion of contaminated food or water can transmit the virus. In the U.S., HAV cases have decreased by 90% in the past 20 years, with roughly 20,000 new cases reported each year according to the Centers for Disease Control and Prevention (CDC). Experts attribute the decline in HAV cases in the U.S. to routine vaccination of children 12 to 18 months.
According to lead author Dr. Umid Sharapov, an epidemiologist with the CDC and his coauthors, this is the first study to examine the effectiveness of a two-dose inactivated hepatitis A vaccine in children younger than two years of age over a ten-year period. In addition, the researchers investigated whether maternal anti-HAV antibody transfer to their children impacts the vaccine protection against HAV.
With parental consent, researchers enrolled full-term infants who were healthy at six-months of age. Mothers were tested for total antibody to HAV. The 197 infants and toddlers were broken into three age groups: group one-infants 6 to 12 months; group two-toddlers between 12 and 18 months; and group three-toddlers 15 to 21 months of age. Each group was randomized by maternal anti-HAV status. HAV antibody levels were measured at one and six months, and additional follow-up took place at three, five, seven and ten years after the second dose of hepatitis A vaccine.
At one month following the second dose of the hepatitis A vaccine children in all groups showed signs of protection from the virus. At the ten-year follow-up most children retained anti-HAV protection. In the first group, 7% and 11% of children born to mother's without and with antibodies to the HAV virus, did not retain HAV protection from vaccination, respectively. Additionally, 4% of group three children born to anti-HAV negative mothers lost HAV protection.
"Our study demonstrates that seropositivity to hepatitis A persists for at least ten years after primary vaccination with two-dose inactivated HAV vaccine when administered to children at ages 12 months and older, regardless of their mothers' anti-HAV status," concludes Dr. Sharapov. "These findings support current CDC/ACIP guidelines for routine administration of two doses of inactivated hepatitis A vaccine to all children in the U.S. beginning at the age of 12 months." The authors point out that a future booster dose may be necessary to maintain protection against HAV and they will continue follow-up participants into their teens to monitor benefit of the initial immunization.
Full citation: "Persistence of Hepatitis A Vaccine Induced Seropositivity in Infants and Young Children by Maternal Antibody Status: 10-Year Follow-Up." Umid M. Sharapov, Lisa R. Bulkow, Susan E. Negus, Philip R. Spradling, Chriss Homan, Jan Drobeniuc, Michael Bruce, Saleem Kamili, Dale J. Hu, Brian J. McMahon. Hepatology; DOI: 10.1002/hep.25687); Print Issue Date: August, 2012. URL: http://onlinelibrary.wiley.com/doi/10.1002/hep.25687/abstract
Author Contact: To arrange an interview with Dr. Sharapov, please contact the news media team at CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention at 404-639-8895 or NCHHSTPMediaTeam@cdc.gov.
This study is published in Hepatology. Media wishing to receive a PDF of this article may contact firstname.lastname@example.org .
About the Journal: Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Our core businesses publish scientific, technical, medical, and scholarly journals, encyclopedias, books, and online products and services; professional/trade books, subscription products, training materials, and online applications and Web sites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
Dawn Peters | EurekAlert!
WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf
First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
24.05.2018 | Physics and Astronomy
24.05.2018 | Health and Medicine
24.05.2018 | Life Sciences